Skandigen Interim report January - September 1996

11/26/1996 6:00 AM EST

- The Group's sales amounted to MSEK 13.3 (11.0) for the period. The consolidated result after depreciation was MSEK -5.3 (-9.2). The result after net financial items amounted to MSEK 5.8 (-9.5). The net financial items include a non-recurring revenue from sale of subscription warrants of MSEK 10.2 (0).
- The subsidiary Fermentech Medical Ltd. got approval in October to start clinical trials of its hyaluronan product for treatment of osteoarthritis.
------------------------------------------------------------
This information was brought to you by Waymaker http://www.waymaker.net

Skanditek

RSS

Skanditek is an industry holding company with ownership interests mainly in Swedish unlisted companies. The portfolio comprises some twenty holdings with focus on information technology, electronics and industrial compon...

CONTACT

SKANDITEK
.+46 8 614 00 20
http://www.skanditek.se

Recent Releases

The merger between Bure and Skanditek has been registered with the Swedish Companies Registration Office
1/27/2010 5:15 AM EST
Permission to implement the merger between Bure and Skanditek granted by the Swedish Companies Registration Office
1/19/2010 7:00 AM EST
Confirmation of important dates in connection with the execution of the merger between Bure and Skanditek
1/18/2010 2:30 AM EST
Extraordinary General Meeting of Skanditek Industriförvaltning AB (publ)
12/1/2009 7:30 AM EST
Information to the shareholders in Skanditek and Bure regarding the merger between the companies
11/16/2009 1:46 PM EST